Clinical Significance of Computer Aided Image Analysis in Treatment Response Evaluation of Lung Cancer

NCT ID: NCT03954847

Last Updated: 2019-05-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-01

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators will evaluate the utility of computer aided image analysis in lung cancer with the aim of predicting treatment response and prognosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Tumor biological behavior is the fundamental cause of heterogeneous prognosis. The features found on medical images are also reflections of the tumor biological behavior. However, the limitations in spatial and intensity resolution of the naked eye are two inevitable shortcomings of image interpretation by naked eyes, resulting in subjective and limited analyses of images. Computer aided image analyses such as radiomic analysis and machine learning methods are emerging as promising image interpretation methods. The natural advantage of the unlimited spatial and intensity resolution of computers can overcome the shortcomings of visual inspection with the naked eye. Moreover, the massive computing power of computer is also far greater than that of humans. This study will focus on the application of computer aided analysis in predicting treatment response and prognosis in lung cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lung cancer patients

Lung cancer patients with PET/CT or CT examination before any cancer-specific treatment

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients \>= 18 years old
2. Pathological diagnosis of NSCLC between 2012 and 2019;
3. PET/CT or CT examination before any cancer-specific treatment;

Exclusion Criteria

1. A time interval between treatment and image examination greater than 1 month;
2. A history of other malignancies
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yang Jin

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yang Jin, MD

Role: CONTACT

027-85755457

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yang Jin, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

WuhanUH-V1.2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Survival Outcomes of Lung Cancer
NCT03647098 RECRUITING
PD-L1 Expression in Lung Cancer
NCT04992715 UNKNOWN PHASE2